UNSPSC 51112512: Mannomustine

This classification denotes a nitrogen mustard compound with the molecular formula C10H22Cl2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E60VWA40D2, chemically known as 1,6-bis(chloroethylamino)-1,6-dideoxy-d-mannite but more generally known as mannomustine, which bears US NIH Compound Identifier 11337. European Medicines Agency schedules Mannomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08643MIG.

UNSPSC 51112512 Mannomustine, a Commodity code, covers pharmaceutical products sourced through state and local health agencies' direct-to-manufacturer procurement initiatives. The Texas Health and Human Services Commission's April 2026 Request for Information on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions exemplifies the scope: state procurement offices are moving away from traditional pharmacy benefit manager and group purchasing organization channels to establish direct contracting relationships with pharmaceutical manufacturers for prescription fulfillment and cost management. This code captures the acquisition of specific pharmaceutical commodities—in this case, mannomustine and similar oncology agents—when state agencies source them through non-traditional, value-based, or outcomes-negotiated pathways rather than conventional wholesale distribution. The issuing bodies under this code are primarily state health departments and related agencies managing pharmacy benefits for state employees, retirees, and Medicaid populations.

The Texas HHS Commission is the standout recent buyer, using an RFI mechanism to gauge vendor readiness for direct-to-manufacturer contracting models that bypass intermediaries. Geographic activity centers on Texas based on the current record. The RFI posted April 3, 2026, with the same response deadline, sought vendor capabilities for implementing direct relationships and outcomes-based pricing arrangements; no formal award value, budget range, or evaluation criteria were announced in this exploratory phase. The state explicitly requested vendor experience with direct contracting for self-insured employers and government health plans, flexibility on net-pricing models without rebates, and capacity to fulfill product volume requirements. This procurement mechanism signals that Texas HHS intends to use vendor responses to shape a subsequent formal RFP with defined financial and temporal parameters; however, no formal solicitation has been issued to date under this code in other jurisdictions reflected in the available record.